Study of REGN2810 in Adults With Cervical Cancer

Status: open

17-253 - An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma

Treatment for Cervical Cancer

Contact Us Or call (251) 445-9834


The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic platinum-refractory cervical cancer treated with either REGN2810 or investigator's choice (IC) chemotherapy. IRB Number 17-253


This trial is sponsored by Regeneron Pharmaceuticals, Inc..

Providers Associated With This Trial

Principle Investigator

  • Rocconi RodneyView Profile
    Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Associate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology

Sub Investigators

    This link will open in a new tab or window.